Protective and Anti-Pathology Effects of Sm Fructose-1,6-Bisphosphate Aldolase-Based DNA Vaccine against Schistosoma mansoni by Changing Route of Injection.
10.3347/kjp.2013.51.2.155
- Author:
Mohamed SABER
1
;
Tarek DIAB
;
Olft HAMMAM
;
Amr KARIM
;
Amina MEDHAT
;
Mamdouh KHELA
;
Ehab EL-DABAA
Author Information
1. Biochemistry Department, Theodor Bilharz Research Institute, P.O. Box 30, 12411, Giza, Egypt.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Schistosoma mansoni;
DNA vaccine;
different vaccination route;
fructose-1,6-bis phosphate aldolase
- MeSH:
Animals;
Antibodies, Helminth/blood;
Disease Models, Animal;
Female;
Fructose-Bisphosphate Aldolase/genetics/*immunology;
Histocytochemistry;
Immunoglobulin G/blood;
Injections, Intramuscular;
Injections, Intraperitoneal;
Injections, Subcutaneous;
Mice;
Parasite Load;
Schistosoma mansoni/enzymology/genetics/*immunology;
Schistosomiasis mansoni/immunology/parasitology/pathology/*prevention & control;
Vaccination/methods;
Vaccines, DNA/administration & dosage/genetics/*immunology;
Vaccines, Synthetic/administration & dosage/genetics/immunology
- From:The Korean Journal of Parasitology
2013;51(2):155-163
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study aimed to evaluate the efficacy of fructose-1,6-bis phosphate aldolase (SMALDO) DNA vaccination against Schistosoma mansoni infection using different routes of injection. The SMALDO has been cloned into the eukaryotic expression vector pcDNA3.1/V5-His TOPO-TA and was used in injecting Swiss albino mice intramuscularly (IM), subcutaneously (SC), or intraperitoneally (IP) (50 microg/mouse). Mice vaccinated with non-recombinant pcDNA3.1 served as controls. Each group was immunized 4 times at weeks 0, 2, 4, and 6. Two weeks after the last booster dose, all mice groups were infected with 80 S. mansoni cercariae via tail immersion. At week 8 post-infection, animals were sacrificed for assessment of parasitological and histopathological parameters. High anti-SMALDO IgG antibody titers were detected in sera of all vaccinated groups (P<0.01) compared to the control group. Both the IP and SC vaccination routes resulted in a significant reduction in worm burden (46.2% and 28.9%, respectively, P<0.01). This was accompanied by a significant reduction in hepatic and intestinal egg counts (41.7% and 40.2%, respectively, P<0.01) in the IP group only. The number of dead eggs was significantly increased in both IP and IM groups (P<0.01). IP vaccination recorded the highest significant reduction in granuloma number and diameter (54.7% and 29.2%, respectively, P<0.01) and significant increase in dead miracidia (P<0.01). In conclusion, changing the injection route of SMALDO DNA vaccination significantly influenced the efficacy of vaccination. SMALDO DNA vaccination via IP route could be a promising protective and anti-pathology vaccine candidate against S. mansoni infection.
